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Upregulation of Death

Introduction
Prostate cancer is the most common cancer in males worldwide [1] . Current medical treatment approaches include surgery, chemotherapy, radiation therapy, hormonal therapy, cryosurgery and high-intensity focused ultrasound [2] . It was well documented that TNFrelated apoptosis-inducing ligand (TRAIL/Apo2L) has been used to induce in several cancers [3] [4] [5] [6] . TRAIL-induced apoptosis pathway is similar to TNF and Fas death receptor pathways including the binding of Fas-associated-death domain (FADD) proteins leading to activation of apoptotic cell death. TRAIL receptors R1, R2, R3 and R4 are known as DR4, DR5, DcR1, and DcR2, respectively [7] .
Though TRAIL is a promising anticancer agent, TRAIL resistance is a major barrier to effective cancer therapy [8] . Notably, prostate cancer cells such as CWR22Rv1, DU145, DuPro, JCA-1, LNCaP, PC-3, PPC-1 and PrEC cells are resistant to 100 ng/ml TRAIL-induced apoptosis [9, 10] . Thus, TRAIL sensitizers from natural sources such as trichostatin A [11] , curcumin [12] , sulforaphane [13] , zyflamend [14] and cardamonin [15] are considered attractive with low toxicity and less resistance in normal cells.
Vitisin A [16] , a complex of resveratrol dimers found in grapes and red wine, is known to have anti-inflammatory effects on RAW 264.7 cells by inhibiting ERK, p38, and NF-kappaB activation [17] , cytotoxic effects on human leukemia cells [18] , anti-migratory activity [19] , anti-adipogenic effects on 3T3-L1 cells [20] , and anti-viral activity in A549 alveolar epithelial cells through interference with Akt and STAT1 phosphorylation [21] . Nevertheless, the underlying apoptotic mechanism of Vitisin A in prostate cancer cells has not been clearly elucidated. Thus, in the present study, the potential of Vitisin A to sensitize PC-3 prostate cancer cells to TRAIL-mediated apoptosis was evaluated by MTT assay, cell cycle analysis, Western blotting, flow cytometric analysis of ROS, and DR5 small interfering RNA (siRNA) transfection assay.
Materials and Methods
Cell culture PC-3, DU 145 and LNCaP prostate cancer cells were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). The cells were cultured in RPMI 1640 (Welgene, New York, USA) supplemented with 10% fetal bovine serum (FBS) (Welgene, New York, USA) and 1 % penicillin-streptomycin (Invitrogen, Carlsbad, CA, USA) at 37°C in a humidified 5% CO 2 atmosphere. Vitisin A (purity >95%) was obtained from Dr. Shi-Yong Ryu from the Korean Research Institute of Chemical Technology (Daejon, Korea).
Cytotoxicity assay
The cytotoxicity of Vitisin A (4 or 8 µM) (Fig. 1A) and/or TRAIL (20 or 40 ng/ml) (Sigma, St. Louis, MO, USA) against PC-3, DU145 and LNCaP prostate cancer cells in 96-well microplates was measured by MTT colorimetric assay. The prostate cancer cells were seeded onto 96-well microplates at a density of 1 × 10 4 cells per well and treated with various concentrations of Vitisin A and/or TRAIL for 24 h. MTT working solution (5 mg/ml in PBS) was added to each well and the plates were incubated at 37°C for 2 h. The optical density (OD) was then measured at 570 nm using a Sunrise microplate reader (TECAN, Männedorf, Switzerland). 
Cellular Physiology and Biochemistry
Apoptosis using flow cytometry with Annexin V and PI staining Annexin V-FITC Apoptosis Detection kit (BioVision, CA, USA) was used to detect apoptotic cells by flow cytometry according to the manufacturer's instructions. Cells were trypsinized and pelleted by centrifugation at 1,000 rpm for 5 min. The pellets were then resuspended in binding buffer (500 μl), added 5 µl of Annexin V-FITC and 5 µl of propidium iodide (50 µg/ml) and incubated at room temperature for 5 min in the dark. Fluorescence intensity was measured by FACS Calibur flow cytometer and analyzed using the CellQuest Pro data analysis software.
Western blotting
Cells (2.5 × 10 5 ) exposed to Vitisin A (4 µM) and/or TRAIL (20 ng/ml) for 24 h were washed with cold PBS and centrifuged. The cells were incubated with RIPA buffer (50 mM Tris-HCl [pH 7.5], 150 mM sodium chloride, 1% Triton X-100, 0.1% SDS, 2 mM EDTA, 0.5 % sodium deoxycholate) on ice for 30 min at 4°C and then centrifuged at 14,000 g for 30 min at 4°C. The protein contents of the supernatants were measured using a DC Protein Assay Kit II (Bio-Rad, Hercules, CA, USA). The proteins were then separated on 4-12% NuPAGE Bis-Tris gels (Invitrogen, New York, USA) and electro-transferred onto Hybond ECL transfer membranes (GE Healthcare Bio-Sciences, Piscataway, NJ,USA). The membranes were blocked with 5% nonfat dry milk and immunoblotted with antibodies against caspase 3, cleaved caspase 3, caspase 7, cleaved caspase 7, caspase 8, PARP, Bcl-2, Bcl-x L , DR4, DR5, FADD, DcR1 and β-actin (Cell Signaling, Danvers, MA,USA).
Measurement of reactive oxygen species (ROS) production by flow cytometry and using a microplate fluorometer PC-3 cells (2.5 × 10
5
) were cultured in a 96-well cell culture plate and then pre-incubated with DCFH-DA for 1 h at 37°C. After incubation, DCFH-DA-loaded cells were treated with Vitisin A (4 µM) and/or TRAIL (20 ng/ml) for 1 h at 37°C. Intracellular levels of ROS were measured by flow cytometry using 2070-diacetyl dichlorofluorescein (DCFDA). ROS production was analyzed using the CellQuest Software with a FACSCalibur flow cytometer. Also, the concentration of DCF was quantified using the OxiSelect Intracellular ROS Assay Kit (Cell Biolabs, CA, USA) and a Fluoroskan Ascent microplate fluorometer (Thomas Scientific, NJ, USA).
Measurement of DR5 cell surface expression by flow cytometry
To detect DR5 cell surface expression, PC-3 (2.5 × 10 5 ) cells exposed to TRAIL (20 ng/ml) and/or Vitisin A (4 µM) for 24 h were incubated with anti-DR5-FITC and anti-mouse IgG antibodies (Abcam, United Kingdom) for 30 min at room temperature. The stained cells were analyzed using the CellQuest Software with the FACSCalibur flow cytometer.
DR5 small interfering RNA transfection PC-3 cells were transiently transfected with a validated scrambled control siRNA vector or a DR5 siRNA plasmid (Santa Cruz Biotechnology, Santa Cruz, CA) using Interferin™ transfection reagent (Polyplus Transfection Inc., New York, NY, USA). Briefly, the mixture of siRNA and Interferin transfection reagent was incubated for 10 min, added to each well containing cells (final siRNA concentration = 40 nM) and incubated at 37°C for 24 h before Vitisin A (4 µM) and TRAIL (20 ng/ml) treatment.
DR5 promoter assay
The pDR5/-605 promoter construct (a gift from Dr. TK Kwon, Keimyung University, Korea) was transfected into PC-3 cells along with a Renilla luciferase reporter plasmid. One day after transfection, cells were treated with Vitisin A (4 µM) and/or TRAIL (20 ng/ml) for 24 h. Luciferase activity was measured using the Dual-Luciferase Reporter Assay System (Promega, Madison, WI, USA).
Statistical analyses
Statistical analyses were conducted using SigmaPlot version 12 (Systat Software Inc., San Jose, CA, USA). All data are expressed as means ± standard deviation (SD). Statistically significant differences between treatments and the control were identified by Student's t-test. (Fig.1 B) .
Combined treatment with Vitisin A and TRAIL significantly increased the sub-G1 population in PC-3, DU145 and LNCaP prostate cancer cells
To confirm whether the cytotoxicity of combined treatment with Vitisin A and TRAIL was due to apoptosis, cell cycle analysis was carried out in PC-3, DU145 and LNCaP prostate cancer cells. As shown in Fig. 2 A and B , combined treatment of Vitisin A (4 µM;V4) and TRAIL (20 ng/ml;T20) for 24 h significantly increased the sub-G1 population (to 21.6±0.1%) in PC-3 cells compared to treatment with Vitisin A (4 µM; 1.7±0.1%) or TRAIL (20 ng/ml; 4.6 ±0.2%) alone. Combined treatment with 4 µM Vitisin A and 40 ng/ml TRAIL (V4T40) significantly increased the sub-G1 population (to 21.9±1.4%) in PC-3 cells compared to treatment with Vitisin A (4 µM; 1.7±0.1%) or TRAIL (40 ng/ml; 10.0±0.6%) alone. Similarly, combined treatment with 8 µM Vitisin A and 20 ng/ml TRAIL (V8T20) significantly increased the sub-G1 population (to 28.7±0.4%) in PC-3 cells compared to treatment with Vitisin A (8 µM;2.7±0.2%) or TRAIL (20 ng/ml; 4.6±0.2%) alone. Consistently, combined treatment of Vitisin A (4 µM;V4) and TRAIL (20 ng/ml;T20) for 24 h significantly increased the early and late apoptosis to 2.85±2.01 %, and 18.24±1.01 %, respectively, in PC-3 cells compared to Vitisin A (4 µM; 1.57±1.19 % and 4.31±0.46 %) or TRAIL (20 ng/ml; 2.01±0.23 % and 5.87±0.48 %) alone by Annexin V and PI staining (Fig. 2 C and D) . Furthermore, combined 
Combined treatment with Vitisin A and TRAIL regulated apoptosis-related proteins and DR5 in PC-3 prostate cancer cells
To determine whether Vitisin A and/or TRAIL affect apoptosis, we assessed the expression levels of pro-apoptotic and anti-apoptotic proteins by Western blotting. As shown in Fig. 3A and B, combined treatment with Vitisin A (4 µM) and TRAIL (20 ng/ml) increased the cleavage of PARP and caspase7/3 and attenuated the expression of pro-caspase 7/8 but not pro-caspase 9 in PC-3 prostate cancer cells. Consistently, combined treatment with Vitisin A (4 µM) and TRAIL (20 ng/ml) suppressed the expression of the anti-apoptotic proteins Bcl-2 and Bcl-XL in PC-3 prostate cancer cells compared to Vitisin A or TRAIL alone (Fig. 3B) . Next, we examined the expression of TRAIL death receptors and its associated proteins such as DR4, DR5, FADD and Dcr1 by Western blotting. As shown in Fig. 4A and B, combined treatment with Vitisin A (4 µM) and TRAIL (20 ng/ml) synergistically upregulated DR4, and DR5 in PC-3 prostate cancer cells, and downregulated the expression of Dcr1, but not FADD compared to Vitisin A or TRAIL alone. However, here we focused on the role of DR5 in combination induced apoptosis in PC-3 cells. Thus, luciferase assay was performed The ratio of DR5/β-actin was determined using the Image J software. (C) Effect of Vitisin A and TRAIL on DR5 promoter activity. DR5 promoter plasmid and Renilla luciferase were transfected into PC-3 cells. After 24 h, Vitisin A (4 µM) and/or TRAIL (20 ng/ml) were added to PC-3 cells. Briefly, luciferase activity was normalized to that of Renilla luciferase and effect of Vitisin A and TRAIL was evaluated on DR5 promoter activity. Data are presented as means ± SD of triplicate samples. ** p<0.01 vs untreated control.
for DR5 promoter activity. A pDR5/-605 promoter construct was transfected into PC-3 cells to determine DR5 activity. As shown in Fig. 4C , combined treatment of Vitisin A (4 µM) and TRAIL (20 ng/ml) for 24 h increased DR5 promoter activity in PC-3 cells compared to Vitisin A or TRAIL alone (Fig. 4C) . To evaluate the cell surface expression of DR5, flow cytometry was used. Combined treatment of Vitisin A (4 µM) and TRAIL (20 ng/ml) effectively moved histogram shift for cell surface expression of DR5 to right in PC-3 cells compared to Vitisin A or TRAIL alone (Fig. 5A , 5B). To investigate the role of DR5 in combined treatment of Vitisin A and TRAIL induced apoptosis, DR5 siRNA transfection assay was used. After transfection with control or DR5 siRNA plasmid in PC-3 cells, Vitisin A and/or TRAIL were added for 24 h in transfected PC-3 cells. Western blotting revealed that silencing of DR5 reduced the ability of combination of Vitisin A and TRAIL to induce PARP cleavage in PC-3 cells compared to untreated control (Fig. 6 ). 
Combined effect of Vitisin A and TRAIL on ROS production in PC-3 prostate cancer cells
Discussion
To assess the potential of Vitisin A as a sensitizer to TRAIL induced apoptosis in prostate cancer cells, current study was performed. Combination of Vitisin A and TRAIL enhanced cytotoxicity compared to Vitisin or TRAIL alone in PC-3 and DU145 prostate cancer cells, implying synergism between Vitisin A and TRAIL. In cell cycle analysis to check whether or not the cytotoxicity of the combination is due to apoptosis, combination of Vitisin A and TRAIL synergistically increased sub-G1 population in PC-3 and DU145 cells compared to Vitisin or TRAIL alone, indicating synergistic apoptotic effect by combination of Vitisin A and TRAIL.
In general, apoptosis, so-called programmed cell death, involves two typical caspasedependent pathways. One is intrinsic mitochondria-dependent apoptosis, in which cytochrome c is released and binds to apoptotic protease activating factor 1 (Apaf-1) and ATP, and then binds to pro-caspase 9 to create an apoptosome to finally activate the effector caspase 3 [22] [23] [24] . The other is extrinsic death receptor-dependent apoptosis. The Fas receptor binds Fas ligand (FasL), a transmembrane protein of the TNF family. Also, the deathinducing signaling complex (DISC), consisting of FADD, caspase 8 and caspase 10, directly activates the execution of apoptosis via caspase 3 [23, 25, 26] . In our study, combination of TRAIL and Vitisin A induced the cleavage of PARP and caspase 3, attenuated the expression of pro-caspase 7/8, and DcR1 but not pro-caspase 9, and activated DR4 and DR5 in PC-3 cells, implying death-receptor-dependent pathway by combination of TRAIL and Vitisin A.
There are accumulating evidences that DR5 upregulation is a promising molecular target for sensitizing tumor cells to TRAIL-induced apoptosis [27] [28] [29] . In the present study, combination of Vitisin A and TRAIL induced DR5 protein expression, significantly enhanced the activity of DR5 promoter and cell surface expression of DR5 in PC-3 cells. Conversely, silencing of DR5 by siRNA transfection also blocked the ability of Vitisin A to induce PARP cleavage in PC-3 cells, strongly demonstrating the important role of DR5 in apoptosis induction by combination of Vitisin A and TRAIL.
It is well documented that ROS plays a critical role in apoptosis induction in several cancers [30] [31] [32] [33] and also ROS mediates TRAIL sensitization through modulation of TRAIL receptor DR5 in prostate cancer cells by several cancer chemopreventive agents such as Orlistat [34] , Celastraol [35] and Baicalein [36] . Our flow cytometric analysis revealed that combination of TRAIL and Vitisin A increased the production of ROS and conversely ROS inhibitor NAC blocked the ability of combination of TRAIL and Vitisin A to cleave PARP in PC-3 cells, indicating the role of ROS in apoptotic effect by combination of TRAIL and Vitisin A. Our findings that combination of TRAIL and Vitisin A induces apoptosis as a potent TRAIL sensitizer are supported by previous evidences that resveratrol sensitized HepG2 [37] , melanoma [38] , neuroblastoma [39] and prostate cancer cells [40] [41] [42] to TRAIL induced apoptosis, since vitisin A is a complex of resveratrol dimers.
In summary, combined treatment with Vitisin A and TRAIL increased cytotoxicity and the sub-G1 population in PC-3, DU145 and LNCap prostate cancer cells, induced apoptosis by cleavage of PARP and caspase 3, inhibited pro-caspases 7/8, DcR1, and activated DR5 in PC-3 cells. Furthermore, the combination of TRAIL and Vitisin A increased the production of ROS. Conversely, ROS inhibitor NAC and silencing of DR5 by siRNA transfection blocked the ability of Vitisin A and TRAIL to induce PARP cleavage in PC-3 cells. These findings suggest that combination of TRAIL and Vitisin A synergistically induces apoptosis in prostate cancer cells via upregulation of DR5 and production of ROS as a potent TRAIL sensitizer.
